Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options

22 Sept 2023

Abstract excerpt

Ovarian cancer is the leading cause of gynecological cancer death. Improved understanding of the biologic pathways and introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) during the last decade have changed the treatment landscape. This has improved outcomes, but unfortunately half the women with ovarian cancer still succumb to the disease within 5 years of diagnosis. Pathways of resistance to PARPi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37737434
DOI: 10.1007/s40265-023-01934-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsPMID 37737434Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategiesSemantic proximity Read ↗

Therapeutic applications of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.